Lorraine Baltzer

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.

Mark G. Kris, Steven M. Grunberg, R J Gralla et al. · Journal of Clinical Oncology · 1994 · 78 citations

Medicine, Pharmacology, Pharmacotherapy +17

Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

Charles W. Young, M. Fanucchi, Declan Walsh et al. · PubMed · 1988 · 62 citations

Medicine, Pharmacokinetics, Pharmacology +14

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer

Gregory T. Wolf, Willard E. Fee, Robert W. Dolan et al. · Head & Neck · 2011 · 58 citations · Full text

Life Sciences, Immunology, Oncology +14

Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.

Max Nolte, R Berkery, Barbara Pizzo et al. · Journal of Clinical Oncology · 1998 · 56 citations

Medicine, Oncology, Pharmacotherapy +16

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Neil L. Berinstein, Gregory T. Wolf, Paul H. Naylor et al. · Cancer Immunology Immunotherapy · 2011 · 46 citations · Full text

Life Sciences, Immunology, Oncology +9